Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
25 hedge funds and large institutions have $8.34M invested in Carisma Therapeutics in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
400% more capital invested
Capital invested by funds: $1.67M → $8.34M (+$6.67M)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
9% more funds holding
Funds holding: 23 → 25 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$1.27M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$41.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.7K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$19K |
| 5 |
Bank of New York Mellon
New York
|
+$9.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$387K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$36.8K |
| 3 |
Goldman Sachs
New York
|
-$36K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
CARM Hedge Fund Activity: Q2 2016 in Review
25 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2016, worth a combined $8.34M — up 400% from $1.67M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CARM positions and 6 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $1.27M. The largest seller was Sabby Management, exiting entirely with an estimated $387K sold.
- 25 institutional investors held Carisma Therapeutics (CARM) as of Q2 2016, up from 23 in Q1 2016.
- Funds reported $8.34M of Carisma Therapeutics stock for Q2 2016, up 400% quarter-over-quarter.
- 10 funds opened new Carisma Therapeutics positions in Q2 2016 and 6 closed out, a net change of +4 holders.
- The largest Carisma Therapeutics buyer in Q2 2016 was Boxer Capital, an estimated $1.27M added.
- The largest Carisma Therapeutics seller in Q2 2016 was Sabby Management, an estimated $387K sold.
Based on aggregated 13F filings for Q2 2016.